Bone marrow is a vital biological resource used to treat people with diseases such as leukemia and lymphoma. In addition, it has been utilized for stem cell therapy, as bone marrow contains a large concentration of these valuable specialty cells. Once harvested, these stem cells can help treat conditions such as autoimmune conditions, orthopedic injuries, and neurodegenerative disease.
What Is Bone Marrow?
Bone marrow is gelatinous, soft tissue that fills the center of bones. There are two general types of bone marrow: myeloid tissue or red bone marrow and fatty tissue or yellow bone marrow.
Bone marrow contains capillaries, blood vessels, and stem cells in varying concentrations. Every day, the average person’s bone marrow produces roughly 220 billion blood cells. The majority of blood cells in the human body come from bone marrow, although some are produced by other sources.
Types of Bone Marrow Stem Cells
While there are two types of bone marrow, there are also two kinds of stem cells within that marrow. The first type of stem cells is called mesenchymal stem cells (MSCs). The second type is the hematopoietic stem cell.
Hematopoietic stem cells are found in the red bone marrow. These cells are blood-forming. MSCs are found in the yellow bone marrow and are alternatively known as marrow stromal cells. These stem cells are responsible for producing bone, cartilage, and fat.
Stem cells can transform into many different types of cells. As a result, providers and doctors use them to treat various medical conditions, including TBI, glaucoma, and osteoarthritis. While stem cell therapy is still being studied, many patients suffering from these conditions have experienced benefits from this treatment option.
What Is Bone Marrow Aspirate?
Bone marrow aspirate is the material removed from within bones. The process is known as bone marrow aspiration. Medical professionals must harvest bone marrow aspirate to perform specific tests and may also use it for stem cell therapy.
When using bone marrow aspirate for stem cell therapy, the medical staff will use a local anesthetic and the patient is awake for the procedure. They will then harvest the bone marrow from a large bone using a thin needle. The pelvis is the most common harvesting location because of its size and the abundance of stem cells it contains.
Once harvested, the stem cells are concentrated and then readministered to the targeted areas or near the point of injury. Over the next few weeks to a few months, the stem cells work to help stimulate the patient’s natural healing capabilities and have the potential to manage and improve symptoms. If you are interested in learning more about the potential benefits of stem cells, contact a Care Coordinator today!
The ability for bone to naturally repair fractures and other common injuries have been well documented. However, research has consistently demonstrated that as they age, bone loses its ability to heal, repair, and fend off various bone diseases. In fact, each year, in the U.S. alone, there are over 2 million fragility-associated fractures with associated healthcare costs exceeding more than $20 billion dollars.
Currently, non-stem cell bone healing therapies including estrogen and related agonists, recombinant parathyroid hormone, supplements such as vitamin D and calcium exist, but with limitations and a number of potentially serious side effects.
Considering that the incidence of fracture and the associate rate of morbidity increase with age, current research is now examining other therapeutic options for the structural and functional restoration of bone, including the viability and of tissue engineering applications such as mesenchymal stem cells (MSCs) and bioscaffolding as potential solutions for the structural and functional restoration of bone.
Stem cells are generally used therapeutically in three distinct ways, including 1.) freshly isolated stem cells transplanted directly into tissue and undergo in vivo differentiation to become a desired cell type; 2.) the stem cell can be manipulated in vitro prior to being implanted; or 3.) circulating endogenous stem cells are recruited by cytokines to facilitate cell proliferation, migration, adhesion, and differentiation.
As researchers continue to explore using MSCs as part of therapeutic bone regeneration, it is generally accepted that MSC bone marrow density and quality decrease with age. In addition, a factor in determining the effectiveness of MSCs related to facilitating tissue repair is the ability for the stem cells to be directed to the site of injury, a process more commonly known as “homing”. A recent study using mice has demonstrated that MSCs appear to lose their homing ability rapidly while young MSCs demonstrate better homing ability, especially when compared to old MSCs. Considering this, future research must consider the age of both donor and recipient when determining the effectiveness of this strategy.
In addition to stem cells, bioscaffolds are also considered an essential component of the bone regeneration strategy, serving as the reservoir for multiple factors, the carrier for cells, the filler for the void space, and the template for bone regeneration. The ideal scaffold for bone tissue engineering has been identified as:
Showing no local and systemic toxic effects to the host tissue
Supporting normal cellular activity
Allowing cell adhesion, proliferation, extracellular matrix deposition, and inducting new bone formation
Prompting the formation of blood vessels after weeks of implantation.
Considering the above, several substrates have been identified as potential bioscaffolds to support improved regeneration of bone tissue, including decellularized extracellular matrix scaffolds, synthetic scaffolds (calcium phosphate-based bioactive ceramic scaffolds; metallic scaffolds (including metal scaffolds coated with growth factors and other bioactive factors); hybrid scaffolds combining two or more materials (metal-ceramic-poly hybrid scaffolds); natural and synthetic polymeric scaffolds; and nanomaterial-based scaffolds.
As research continues to explore the possibilities of new therapeutic approaches to bone healing provided through various tissue engineering applications, the use of MSCs and bioscaffolds continue to demonstrate potential benefits. Among the key areas requiring further study is the need to develop vascularization in engineered bone material. Bone and bone tissue has a rich vascular supply; while the recent study has demonstrated nanomaterials as having the potential to promote vascularization (without the aid of growth factors), further research and clinical trial are required.
Researchers have recently established that a hallmark of Amyotrophic Lateral Sclerosis (ALS) is endothelial cell degeneration that leads to vascular pathology. When this vascular pathology occurs, damage develops to the barrier between the blood and the central nervous system. Given this new understanding of the pathophysiology of ALS, researchers have begun looking at the potential of repairing this barrier as a strategy for treating the disease with bone marrow stem cells.
A recent study, published in Scientific Reports, addressed this issue by testing how human bone marrow cells may impact blood-spinal cord barrier repair by transplanting these cells in an ALS model. The researchers hypothesized that the cells should help to repair the barrier, reversing the damage accompanying ALS. They were also interested in whether this type of repair may improve not only the integrity of the barrier between the blood and central nervous system but also improve symptoms of ALS.
What the researchers found was that the human bone marrow cells differentiated into the type of endothelial cells that were needed for repair and successfully engrafted into the capillaries of the spinal cord in their model. Several specific observations led the scientists to conclude that these stem cells helped to effectively restore the barrier between the blood and the spinal cord.
The stem cells improved the integrity and survival of nervous system cells, including astrocytes and spinal cord motor neurons, preventing problematic changes in these cells that are associated with the breakdown of the blood-central nervous system barrier. Critically, the implantation of the stem cells also led to improvements in behaviors associated with ALS.
While there is still a lot of research to be done to establish whether bone marrow stem cells can help repair the blood-spinal cord barrier in patients with ALS, this study provides promising data. Given that there is no cure for ALS and limited treatment options, there is likely to be an emphasis on cell-based therapies for the disease. As more data become available, we will get a clearer picture as to if and how stem cells can help ALS patients.
Reference: Garbuzova-Davis,S. (2017). Endothelial and astrocytic support by human bone marrow stem cell grafts into symptomatic ALS mice towards blood-spinal cord barrier repair. Scientific Reports, 7(884).
Multiple Sclerosis is a disease of the nervous system that involves the demyelination of nerve cells. As nerve cells lose their myelination, it becomes harder for the cells to communicate with one another. Though there are a number of treatment options for multiple sclerosis, which usually involve immunosuppressants, the conventional treatments do not always work over the long-term and may be associated with unwanted side effects. Given the promising results of stem cells being used in treatments for other nervous system diseases, scientists have reasoned that stem cells could provide a valuable therapy for those with multiple sclerosis.
A recent study published in Cytotherapy has demonstrated for the first time the use of neural progenitors derived from bone marrow mesenchymal stem cells. According to the authors of the study, it has previously been recognized that these cells have the potential to help with multiple sclerosis therapy, whether they come from multiple sclerosis patients or those without multiple sclerosis. Preclinical research has also shown that the use of these stem cells can improve disease in multiple sclerosis models and lead to the recruitment of progenitors to sites of inflammation.
In the current study, scientists wanted to establish the safety and dosing of intrathecal neural progenitors derived from bone marrow mesenchymal stem cells in the treatment of multiple sclerosis and investigated the use of these cells in six patients with progressive multiple sclerosis who were not responding to conventional treatments. The patients were treated with between 2 and 5 injections of the stem cells, and they were evaluated for an average of 7.4 years following their first injection.
Not only were there no safety issues that arose with any of the treated patients, but 4 of the 6 patients demonstrated measurable clinical improvement through the use of stem cell treatment. The results of this pilot study provide support for both the tolerability and effectiveness of stem cell therapy for multiple sclerosis. Future research will help to clarify the specific protocols that may be used to achieve the desired results in this group of patients.
Reference: Harris, VK, Vyshkina, T, & Sadaiq, SA. (2016). Clinical safety of intrathecal administration of mesenchymal cell-derived neural progenitors in multiple sclerosis. Cytotherapy, 18(12), 1476-1482.
Mesenchymal stem cells have two unique and powerful properties that make them the focus of intense scientific research. First, mesenchymal stem cells can escape recognition by the immune system. In other words, when mesenchymal stem cells are infused into the body, the immune system does not recognize them as foreign and does not react to them. If the immune system did respond to the stem cells, it would cause an aggressive and potentially deadly allergic or immunologic response. Second, mesenchymal stem cells have the power to inhibit the immune system. This means mesenchymal stem cells could be used to treat immunological and autoimmune diseases such as Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis, and Crohn’s Disease, among others. In essence, mesenchymal stem cells can affect the immune system without triggering an inflammatory response making them an ideal treatment for these diseases.
For some time, mesenchymal stem cells extracted from bone marrow were thought to be the only type of mesenchymal stem cells capable of beneficially affecting the immune system. This fact is not necessarily bad, but it does mean that mesenchymal stem cell donors must undergo a bone marrow procedure, which can be painful and expensive. It would be far better if doctors could use mesenchymal stem cells taken from easier-to-get tissues such as fat (adipose), umbilical cord blood, or Wharton’s jelly (umbilical cord tissue). Most people have adequate amounts of fat just under the skin, and umbilical cord blood and tissue are thrown away as medical waste every day.
Fortunately for patients, Dr. Yoo and colleagues showed that mesenchymal stem cells taken from fat tissue, umbilical cord blood, and Wharton’s jelly exhibit the same immunomodulatory properties as mesenchymal stem cells taken from bone marrow. The researchers showed that these types of mesenchymal stem cells were able to suppress T-cell proliferation as effectively as those cells taken from bone marrow. T-cell proliferation, it should be pointed out, is a key step in autoimmune inflammation that occurs in diseases such as rheumatoid arthritis and others.
In short, mesenchymal stem cells taken from easier-to-get tissues were just as effective at suppressing inflammation (in vitro) as those taken from bone marrow. These results will need to be confirmed in clinical studies; however, this approach will be much more convenient and less expensive for patients and donors if they can use mesenchymal stem cells taken from fat or umbilical cord rather than bone marrow and yet reap the same benefits.
Reference: Yoo KH et al. (2009). Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. Cell Immunology. 2009;259(2):150-6.
The knee is a complex joint that must support the weight of the body while allowing the leg to bend freely. An important part of the knee joint is the meniscus. The meniscus is a fibrous cartilage structure that acts as a shock absorber. While these menisci perform very well during various strenuous activities, they can and do tear. In fact, a torn meniscus in the knee is one of the most common orthopedic injuries.
A torn meniscus of the knee often causes pain and swelling in the knee. Patients with a torn meniscus cannot squat or kneel, and the knee joint does not move smoothly. In fact, many patients with a torn meniscus describe the joint as popping, locking, catching or even “giving out.”
The meniscus of the knee can be torn in several ways; however, most torn menisci result from either one of two things: athletic activity or degenerative arthritis. As you would imagine, menisci torn during sport occur more commonly in young athletes such as dancers, certain kinds of track and field athletes, and basketball, soccer and football players. People with degenerative arthritis tend to be older and often have careers that require a lot of bending at the knee, such as carpet layers, carpenters, plumbers, etc.
Some people can live with small tears in their knee meniscus, but many people ultimately require surgery to fix the problem. One of the major approaches is to perform a total or partial meniscectomy of the damaged knee meniscus. Generally speaking, surgeons offer partial meniscectomy because patients heal faster, and results are about as good as a total meniscectomy. Unfortunately, surgical repair of these tissues is not always successful, especially in older individuals with tears related to degenerative arthritis. Consequently, surgical researchers are keen to discover new ways to improve partial meniscectomy to help people with meniscal tears of the knee.
One exciting option is using stem cells to potentially help patients regrow healthy meniscus after surgeons remove the damaged portion.
In one study, orthopedic surgeons at various surgical centers around the United States participated in an I/II, randomized, double-blind, controlled study to study the effects of human mesenchymal stem cells in people with a meniscal tear of the knee. Researchers recruited 60 patients who were eligible to receive a partial meniscectomy and sorted them into three groups: treatment group A received 50 million human mesenchymal stem cells, group B received 150 million stem cells, and group C (the control group) simply received an infusion of salt water. Patients received an injection of stem cells into the knee, 7 to 10 days after their partial meniscectomy surgery. Then researchers followed the patients for six weeks, six months, one year, and two years after the procedure.
Researchers found that some patients who received human mesenchymal stem cells had a significant increase in the size of their menisci after surgery. By contrast, no single patient in the control group had an increase in the size of their menisci. In other words, stem cells were found to be able to increase the size of the knee meniscus in some patients, as originally hypothesized. Likewise, the study authors could find no clinically important safety issues from injecting stem cells into the knees of patients. Perhaps most importantly, people who received mesenchymal stem cells reported a significant reduction in the amount of pain they experienced due to degenerative changes in the knee. In other words, partial meniscectomy plus stem cells apparently helped patients with degenerative arthritis of the knee.
The authors concluded that this research shows that human mesenchymal stem cells have the potential to be able to repair knee meniscus tissue and improve knee pain in people with meniscal tears. While additional research is needed, these results are very exciting for people who have torn menisci, especially older patients whose knee pain is a result of osteoarthritis or degenerative joint disease in the knee.
Stemedix, Inc. Bayfront Medical Plaza 601 7th Street S. Suite 565 Saint Petersburg, FL 33701, USA
This website and its contents are not intended to treat, cure, diagnose, or prevent any disease. Stemedix, Inc. shall not be held liable for the medical claims made by patient testimonials or videos. They are not to be viewed as a guarantee for each individual. The efficacy for some products presented have not been confirmed by the Food and Drug Administration (FDA).
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.